Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Director Retirement. On December 20, 2016, Marsha H. Fanucci notified Momenta Pharmaceuticals, Inc. (the “Company”) that she will retire from the Company’s Board of Directors (the “Board”), effective December 31, 2016. Ms. Fanucci has served as a director since March 2005 and currently serves as the chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Ms. Fanucci’s retirement was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session down -0.30 at 14.95 with 356,468 shares trading hands.